Display options
Cite
Feng G, Yang Y, Chen J, et al. Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure. Am J Transl Res. 2016;8(2):1295-301
Feng, G., Yang, Y., Chen, J., Wu, Z., Zheng, Y., Li, W., Dai, W., Guan, P., & Zhong, C. (2016). Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure. American journal of translational research, 8(2), 1295-301.
Feng, Guangqiu, et al. "Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure." American journal of translational research vol. 8,2 (2016): 1295-301.
Feng G, Yang Y, Chen J, Wu Z, Zheng Y, Li W, Dai W, Guan P, Zhong C. Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure. Am J Transl Res. 2016 Feb 15;8(2):1295-301. eCollection 2016. PMID: 27158417; PMCID: PMC4846974.
Copy Download .nbib Format: NLM
Share it on

Am J Transl Res. 2016 Feb 15;8(2):1295-301. eCollection 2016.

Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.

American journal of translational research

Guangqiu Feng, Yu Yang, Juan Chen, Zhiyong Wu, Yin Zheng, Wei Li, Wenxin Dai, Pin Guan, Chunrong Zhong

Affiliations

  1. Department of Gerontology Xiangya Second Hospital of Central South UniversityChangsha 410011, China; Health Care Center, Hainan Provincial People HospitalHaikou 570311, China.
  2. Department of Gerontology Xiangya Second Hospital of Central South University Changsha 410011, China.
  3. Health Care Center, Hainan Provincial People Hospital Haikou 570311, China.

PMID: 27158417 PMCID: PMC4846974

Abstract

As a new anti-anginal agent, ranolazinehas been shown to play a cardioprotective role in regulating myocardial ischemic injury. Given that plasma norepinephrine (NE) and brain natriuretic peptide (BNP, also termed B-type natriuretic peptide-45 in rats) are considered neuron-hormones to indicate heart failure progression. This study aims to examine effects of ranolazine on plasma NE and BNP-45 of rats with chronic ischemic heart failure (CHF). CHF was induced by myocardial infarction following ligation of a left anterior descending artery in adult Sprague-Dawley rats. We hypothesized that ranolazine attenuates the elevated levels of NE and BNP-45 observed in CHF rats thereby leading to improvement of the left ventricular function. Results showed that levels of plasma NE and BNP-45 were increased in CHF rats 6-8 weeks after ligation of the coronary artery. Our data demonstrate for the first time that ranolazine significantly attenuated the augmented NE and BNP-45 induced by CHF (P<0.05 vs. saline control). In addition, a liner relation was observed between NE/BNP-45levels and left ventricular fractional shortening as indication of left ventricular function (r=0.91 and P<0.01 for NE; and r=0.93 and P<0.01 for BNP-45) after administration of ranolazine. In conclusion, CHF increases the expression of NE and BNP-45 in peripheral circulation and these changes are related to the left ventricular function. Ranolazine improves the left ventricular function likely by decreasing heightened NE and BNP-45 induced by CHF. Therefore, our data indicate the role played by ranolazine in improving cardiac function in rats with CHF.

Keywords: Ranolazine; brain natriuretic peptide; myocardial infarction; norepinephrine

References

  1. Circulation. 1986 May;73(5):913-9 - PubMed
  2. Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1923-9 - PubMed
  3. J Cardiovasc Pharmacol. 2011 Jun;57(6):639-47 - PubMed
  4. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10 - PubMed
  5. J Pharmacol Exp Ther. 2007 Apr;321(1):213-20 - PubMed
  6. Cardiovasc Drugs Ther. 2014 Oct;28(5):469-75 - PubMed
  7. Eur J Pharmacol. 2012 May 15;683(1-3):211-6 - PubMed
  8. Circulation. 2000 Feb 22;101(7):784-9 - PubMed
  9. Am J Hypertens. 2015 Sep;28(9):1083-90 - PubMed
  10. Basic Res Cardiol. 1990;85 Suppl 1:305-21 - PubMed
  11. Clin Cardiol. 2003 Apr;26(4):161-2 - PubMed
  12. Am J Transl Res. 2015 Sep 15;7(9):1602-11 - PubMed
  13. Clin Chem. 2010 Jan;56(1):121-6 - PubMed
  14. Am J Physiol. 1989 Dec;257(6 Pt 2):H1886-94 - PubMed
  15. Int J Cardiol. 2013 Nov 15;169(4):262-70 - PubMed
  16. Cardiovasc Pathol. 2007 Mar-Apr;16(2):79-84 - PubMed
  17. Heart. 2006 Jul;92 Suppl 4:iv1-iv5 - PubMed
  18. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):93A-98A - PubMed
  19. Hypertension. 2002 Mar 1;39(3):803-8 - PubMed
  20. Am J Cardiol. 2006 Nov 15;98 (10 ):1322-8 - PubMed
  21. J Cardiovasc Pharmacol Ther. 2014 Sep;19(5):457-69 - PubMed
  22. Am J Physiol Regul Integr Comp Physiol. 2001 Nov;281(5):R1734-45 - PubMed
  23. Hypertension. 2006 Feb;47(2):143-4 - PubMed
  24. Clin Pharmacokinet. 2006;45(5):469-91 - PubMed
  25. Am J Cardiol. 2014 Mar 15;113(6):1075-82 - PubMed
  26. Postgrad Med. 2013 Nov;125(6):43-52 - PubMed
  27. Eur Heart J. 1990 Apr;11 Suppl A:39-43 - PubMed
  28. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):464-71 - PubMed
  29. Circulation. 2003 Mar 11;107(9):1278-83 - PubMed
  30. JAMA. 2004 Jan 21;291(3):309-16 - PubMed
  31. N Engl J Med. 1984 Sep 27;311(13):819-23 - PubMed

Publication Types